Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fluspirilene→

Fluspirilene Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1841-19-6
Molecular formula
C29H31F2N3O
Molecular weight
475.6 g/mol
Drug class
Diphenylbutylpiperidine antipsychoticdopamine D2 receptor antagonist (depot formulation)
Mechanism of action
Antagonises central dopamine D2 receptors, reducing dopaminergic signalling associated with psychotic symptoms. The depot formulation provides prolonged exposure following intramuscular administration.
Indications / reported uses
  • Maintenance treatment of schizophrenia and other chronic psychotic disorders in countries where fluspirilene depot products remain authorised; not intended for rapid control of acute agitation

Sources: NLM MeSH — Fluspirilene · PubMed — Fluspirilene depot antipsychotic · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fluspirilene Environmental Risk Assessment (ERA) (the Fluspirilene ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.